BRCA2 and prostate cancer: We show here that gain of BRCA2 expression in castration-resistant prostate cancer cells confers resistance to 6-TG- and olaparib-induced apoptosis but sensitivity to two 6-TG analogues, namely 2-N-6-BP and 2,6-DTP.